First FDA-Approved Fecal-Based Treatment Helps Fight a Tough Superbug
THURSDAY, Dec. 1, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridium difficile (C. diff) infections. “Today’s approval of Rebyota is an advance in caring for patients who have recurrent C. difficile infection [CDI],”Continue Reading